• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.
【24h】

Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.

机译：Abatacept：首个T淋巴细胞共刺激调节剂，用于治疗类风湿关节炎。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis (RA) is a multisystem autoimmune disease, of unknown aetiology with high morbidity and significantly increased mortality. Over recent years, the introduction of targeted therapies with biologic agents have made major inroads to the outcomes in RA.The first such agents developed were TNF-alpha inhibitors. However, despite their high efficacy, up to 30% patients fail to respond adequately, or develop adverse reaction to TNF-alpha inhibitors. This suggests that other pathological mechanisms are involved, in addition to those mediated by TNF-alpha. Abnormal T-cell function has long been thought to play a key role in the pathogenesis of RA, stimulating both the production of pro-inflammatory cytokines and recruitment of other inflammatory cells, resulting in joint destruction and systemic disease. Abatacept, the first of a group of T-cell co-stimulation modulators, targeting T-cell activation, has recently been licensed for use in RA and shows promise as a useful drug to treat this major disabling disease.
机译：类风湿关节炎（RA）是一种多系统自身免疫性疾病，病因不明，发病率高，死亡率显着增加。近年来，以生物制剂为靶点的治疗方法已使RA取得了重大进展，最早开发的这类药物是TNF-α抑制剂。但是，尽管疗效很高，但仍有多达30％的患者无法对TNF-α抑制剂产生足够的反应或产生不良反应。这表明除了由TNF-α介导的那些之外，还涉及其他病理机制。长期以来，人们一直认为异常的T细胞功能在RA的发病机制中起着关键作用，既刺激促炎性细胞因子的产生，又刺激其他炎性细胞的募集，从而导致关节破坏和全身性疾病。 Abatacept是靶向T细胞活化的T细胞共刺激调节剂中的第一个，最近已获准在RA中使用，并显示出有望作为治疗这种主要致残性疾病的有用药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号